Upregulation of immune checkpoints such as LAG-3, TIM-3 and BTLA by immune cells has been described following PD-1, PD-L1 and CTLA4 inhibition and was linked with enhanced resistance to these drugs in NSCLC [108, 109]. Here, BTLA is linked to non-small cell lung carcinoma.